Comment on: Impact of switching from ranibizumab to aflibercept on the number of intravitreous injection and follow up visit in wet AMD: results of real-life ELU study
- PMID: 34282403
- PMCID: PMC8243194
- DOI: 10.18240/ijo.2021.07.26
Comment on: Impact of switching from ranibizumab to aflibercept on the number of intravitreous injection and follow up visit in wet AMD: results of real-life ELU study
Similar articles
-
Impact of switching from ranibizumab to aflibercept on the number of intravitreous injection and follow up visit in wet AMD: results of real life ELU study.Int J Ophthalmol. 2020 Feb 18;13(2):252-256. doi: 10.18240/ijo.2020.02.08. eCollection 2020. Int J Ophthalmol. 2020. PMID: 32090034 Free PMC article.
-
Short-term outcomes of switching anti-VEGF agents in eyes with treatment-resistant wet AMD.BMC Ophthalmol. 2015 Apr 11;15:40. doi: 10.1186/s12886-015-0025-z. BMC Ophthalmol. 2015. PMID: 25885684 Free PMC article.
-
Ranibizumab and aflibercept for the treatment of wet age-related macular degeneration.Expert Opin Biol Ther. 2015;15(9):1349-58. doi: 10.1517/14712598.2015.1057565. Epub 2015 Jun 16. Expert Opin Biol Ther. 2015. PMID: 26076760 Review.
-
[Switching Therapy from Ranibizumab and/or Bevacizumab to Aflibercept in Neovascular Age-Related Macular Degeneration (AMD): One-Year Results].Klin Monbl Augenheilkd. 2016 Aug;233(8):945-50. doi: 10.1055/s-0042-101348. Epub 2016 Apr 28. Klin Monbl Augenheilkd. 2016. PMID: 27123887 German.
-
Aflibercept administration in neovascular age-related macular degeneration refractory to previous anti-vascular endothelial growth factor drugs: a critical review and new possible approaches to move forward.Angiogenesis. 2015 Oct;18(4):397-432. doi: 10.1007/s10456-015-9483-4. Epub 2015 Sep 7. Angiogenesis. 2015. PMID: 26346237 Review.
References
-
- Muftuoglu IK, Freeman WR. High-frequency aflibercept injections in persistent neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2017;255(10):2069. - PubMed
-
- Gharbiya M, Cruciani F, Mariotti C, Grandinetti F, Marenco M, Cacace V. Choroidal thickness changes after intravitreal antivascular endothelial growth factor therapy for age-related macular degeneration: ranibizumab versus aflibercept. J Ocular Pharmacol Ther. 2015;31(6):357–362. - PubMed
-
- Julien S, Biesemeier A, Taubitz T, Schraermeyer U. Different effects of intravitreally injected ranibizumab and aflibercept on retinal and choroidal tissues of monkey eyes. Br J Ophthalmol. 2014;98(6):813–825. - PubMed
-
- Spaide RF, Jaffe GJ, Sarraf D, Freund KB, Sadda SR, Staurenghi G, Waheed NK, Chakravarthy U, Rosenfeld PJ, Holz FG, Souied EH, Cohen SY, Querques G, Ohno-Matsui K, Boyer D, Gaudric A, Blodi B, Baumal CR, Li XX, Coscas GJ, Brucker A, Singerman L, Luthert P, Schmitz-Valckenberg S, Schmidt-Erfurth U, Grossniklaus HE, Wilson DJ, Guymer R, Yannuzzi LA, Chew EY, Csaky K, Monés JM, Pauleikhoff D, Tadayoni R, Fujimoto J. Consensus nomenclature for reporting neovascular age-related macular degeneration data. Ophthalmology. 2020;127(5):616–636. - PMC - PubMed
LinkOut - more resources
Full Text Sources